These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19497743)

  • 1. An efficient chemical approach to bispecific antibodies and antibodies of high valency.
    Gavrilyuk JI; Wuellner U; Salahuddin S; Goswami RK; Sinha SC; Barbas CF
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3716-20. PubMed ID: 19497743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
    Gavrilyuk JI; Wuellner U; Barbas CF
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
    Li LS; Rader C; Matsushita M; Das S; Barbas CF; Lerner RA; Sinha SC
    J Med Chem; 2004 Nov; 47(23):5630-40. PubMed ID: 15509162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
    Liu Y; Goswami RK; Liu C; Sinha SC
    Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
    Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
    Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple catalytic aldolase antibodies suitable for chemical programming.
    Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides.
    Willmann JK; Kimura RH; Deshpande N; Lutz AM; Cochran JR; Gambhir SS
    J Nucl Med; 2010 Mar; 51(3):433-40. PubMed ID: 20150258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways.
    Castel S; Pagan R; Mitjans F; Piulats J; Goodman S; Jonczyk A; Huber F; Vilaró S; Reina M
    Lab Invest; 2001 Dec; 81(12):1615-26. PubMed ID: 11742032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin αvβ3 and LHRH Receptor Double Directed Nano-Analogue Effective Against Ovarian Cancer in Mice Model.
    Qi N; Zhou X; Ma N; Zhang J; Wang Z; Zhang X; Li A
    Int J Nanomedicine; 2024; 19():3071-3086. PubMed ID: 38562611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Affinity RGD-Knottin Peptide as a New Tool for Rapid Evaluation of the Binding Strength of Unlabeled RGD-Peptides to α
    Bernhagen D; De Laporte L; Timmerman P
    Anal Chem; 2017 Jun; 89(11):5991-5997. PubMed ID: 28492301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
    Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
    Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion.
    Pedchenko V; Zent R; Hudson BG
    J Biol Chem; 2004 Jan; 279(4):2772-80. PubMed ID: 14610079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.
    Liu S
    Bioconjug Chem; 2009 Dec; 20(12):2199-213. PubMed ID: 19719118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
    Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
    Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins.
    Ocampo-García BE; Santos-Cuevas CL; De León-Rodríguez LM; García-Becerra R; Ordaz-Rosado D; Luna-Guitiérrez MA; Jiménez-Mancilla NP; Romero-Piña ME; Ferro-Flores G
    Nucl Med Biol; 2013 May; 40(4):481-7. PubMed ID: 23618768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
    Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
    Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.
    Mould AP; Craig SE; Byron SK; Humphries MJ; Jowitt TA
    Biochem J; 2014 Dec; 464(3):301-13. PubMed ID: 25333419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligands for mapping alphavbeta3-integrin expression in vivo.
    Schottelius M; Laufer B; Kessler H; Wester HJ
    Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging.
    Su ZF; Liu G; Gupta S; Zhu Z; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2002; 13(3):561-70. PubMed ID: 12009947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.